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found between 10-year TTO utility and FACT-BR scores (p<0.01), 10-year TTO 
utility and MDASI-BT (Sleep) scores (p=0.039), 5-year TTO utility and FACT-BR 
scores (p<0.01), and 5-year TTO utility and MDASI-BT (Sleep) scores (p=0.039). 
NCF and KPS scores were not significantly associated with TTO utility. The 
analysis of within-patient changes over time indicated significant mean group 
increases in 10-year TTO utility (p=0.021) and NCF (HVLT-R Total Recall) scores 
(p=0.032); however, KPS score significantly decreased (p<0.01). CONCLUSIONS: 
Patients’ quality of life and sleep disturbance symptoms have significant but 
small effects on the patients’ willingness to trade time. The lack of correlation 
between TTO utility and functional status as well as cognitive function suggests 
that patients’ preferences for better health and for quantity of life are primarily 
influenced by the expected length of time until death and not by their current 
health state.  
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OBJECTIVES: To evaluate the quality of life (QoL) among women with cervical 
lesions using the EuroQol EQ-5D instrument to establish utilities of health states 
in mainland China. METHODS: Patients with cervical precursor lesions and 
cancer were recruited from the West China Second Affiliated Hospital between 
May 2010 and January 2011. They were surveyed with the EQ-5D prior to 
treatment, and at 1, 3 and 6 months after treatment. We calculated QoL scores 
through the five-item descriptive system of health states of the EQ-5D and the 
classic UK preference weighting system. RESULTS: A total of 194 women 
completed the questionnaire, including 78 with cervical precursor lesions, 85 
with early cervical cancer (FIGO Stage Ia, Ib and IIa), and 31 with advanced 
cervical cancer (FIGO stage IIb+).  Statistically significant differences were noted 
in QoL scores between different stages of cervical lesions (F=33.94, P<0.001) and 
between different time points (F=23.41, P<0.001). Pairwise comparisons showed 
that there was a consistent decline in the QoL scores in the spectrum of cervical 
lesions at each time point after treatment (all P<0.05). There existed an 
increasing trend in the timeline of treatment among women with cervical 
precursor lesions, though the QoL scores were not statistically different between 
3 and 6 months after treatment (P=0.099). For early cervical cancer, the QoL 
scores declined in the first month of treatment (P=0.057), and increased to a 
higher level than prior to treatment at 6 months (P<0.001). Despite a statistical 
difference between 1 and 6 months after treatment (P=0.016), advanced cervical 
cancer showed a similar secular trend. CONCLUSIONS: Women with early stage 
of cervical lesion have better QoL than those with late stage of disease. The QoL 
improves for cervical precursor lesions as treatment continues, while it declines 
for cervical cancer patients in the immediate time after treatment and increases 
afterwards.  
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OBJECTIVES: Next generation genomic sequencing is a promising transformative 
technology; however, little is known about factors that influence patients’ 
preferences for the return of incidental findings that are likely to be an inevitable 
aspect of genome sequencing. The objective of this study was to identify the 
attributes of incidental findings important to patients and develop a discrete 
choice experiment (DCE) to quantify patient preferences. METHODS: An initial 
set of key attributes and levels was developed from a literature review and in 
consultation with experts. The attributes’ salience and comprehension were 
refined using focus groups (FG) (2 groups, N=12 total) and cognitive interviews 
(CI) (N=6) with patients who received genetic testing for familial colorectal cancer 
or polyposis syndromes. The attributes and levels used in the hypothetical 
choices presented to FG and CI participants were constructed using an 
orthogonal main-effects experimental design. RESULTS: Overall, we observed a 
wide range of preferences for genomic sequencing information; however, 
patients tended to focus on the importance of several consistent attributes in 
describing their preferences. The final DCE instrument incorporates the 
following attributes and levels: lifetime risk of developing the disease (5%, 40%, 
70%); disease treatability (medical intervention available, lifestyle intervention 
available, or none); disease severity (mild, moderate, severe); carrier status (yes, 
no); drug response likelihood (high, moderate, none), and out-of-pocket test cost 
($250, $425, $1000, $1900). CONCLUSIONS: Individual patient preferences for 
incidental genomic findings are likely influenced by a complex set of diverse 
attributes. This study identified an initial set of important factors, though further 
research is needed to explore preferences in different settings and to develop 
effective ways of helping patients and providers understand and address these 
preferences in the return of incidental findings. Measuring preferences using 
DCE instruments may facilitate patient-provider communication by quantifying 
patients’ personal utility for particular attributes of incidental findings.  
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OBJECTIVES: To identify possible changes in patient-reported outcomes (PRO), 
including health-related quality of life (HRQoL), of multiple myeloma (MM) 
patients undergoing treatment in the USA. PRO of those meeting CRAB criteria 
(hyperCalcemia, Renal insufficiency, Anemia, Bone lesions) for 
active/symptomatic MM was assessed at baseline and 1 year post-baseline. 
METHODS: Data were collected in Connect® MM, an ongoing prospective US 
disease registry of MM patients. Clinicians reported patient demographics and 
clinical characteristics. PRO were recorded at baseline, within 2 months of 
diagnosis, and 1 year post-baseline by completing Brief Pain Inventory (BPI), EQ-
5D, and Functional Assessment of Cancer Therapy (FACT)-MM questionnaires. 
Mean (± standard deviation) BPI, EQ-5D, and FACT-MM change scores were 
analyzed. Statistical significance was assessed. RESULTS: Overall, 636 patients 
(from 189 centers) meeting CRAB criteria provided data at baseline and 1 year 
post-baseline. The majority of patients were male (58%), white (84%), with a 
mean age of 66 (±11) years. Patients were seen in academic (17%), community 
(81%), or government (2%) clinical centers. Evaluable International Staging 
System stages were: I (29% of patients); II (35%); and III (35%). Average pain 
improved over 1 year (P < 0.0005). HRQoL/functional ability improved in 4 of 5 
FACT domains (except social/family; all others P < 0.0001), and in 4 of 5 EQ-5D 
domains (except pain/discomfort; all other P values ranged from 0.0142 to  
< 0.0001). Overall HRQoL, as shown by FACT-MM and FACT-General total scores, 
also improved (both P< 0.0001). Overall HRQoL improved in males and females, 
and in younger age groups (<65 and 65–74 years), but not in those ≥ 75 years. 
CONCLUSIONS: Connect® MM findings indicate that most PRO improved 
between baseline and 1 year post-baseline. Data will be examined to identify 
which disease- and treatment-related factors are associated with HRQoL 
improvement in this MM population.  
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OBJECTIVES: Existing measures of opioid-induced constipation (OIC) symptoms 
have not been developed in accordance with FDA’s 2009 Guidance for Patient-
Reported Outcome (PRO) Measures. The OIC Rating Scale (ORS) was developed 
based on literature and comprehensive qualitative research. This study aimed to: 
1) validate a conceptual framework of two domains; 2) determine the optimal 
scoring system; 3) examine item- and scale-level psychometrics; and 4) establish 
domain responder definitions (RD). METHODS: ORS was administered to 215 US 
adults with OIC in a Phase II study. Confirmatory factor analysis (CFA) was used 
to test the fit of the previously developed conceptual framework. The evaluation 
analyzed data from the 2-week baseline period and the 5-week treatment period. 
Item response theory (IRT) was used to determine an optimal scoring approach, 
followed by classical psychometrics including item- and scale-level reliability, 
and convergent validity. Distribution- and anchor-based approaches were used 
to determine the RD for each domain based on week 5 change from baseline. 
RESULTS: Based on descriptive statistics, item-level correlations, and CFA results 
(confirmatory fit index/non-normed fit index >0.96, standardized root mean 
residual <0.04), a two-domain structure of the ORS was validated and carried 
forward in tests of reliability (αs > 0.85, test-retest ICCs >0.60) and validity 
analyses (convergent rs 0.37-0.55), and to establish score interpretation. IRT 
results provided no compelling evidence requiring special item weights rather 
than a simple raw sum-score per domain. The two-item bowel movement 
symptom (BMS) domain RD = 2 and six-item gastrointestinal-related symptom 
(GRS) domain RD = 4. CONCLUSIONS: The ORS instrument demonstrated strong 
psychometric characteristics using analyses following the current FDA guidance 
for PRO measures. The two domains explained the correlations among the bowel 
movement and gastrointestinal-related symptoms in OIC. These results support 
further use of this instrument in studies of potential treatments for OIC.  
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OBJECTIVES: Metastatic castration-resistant prostate cancer (mCRPC) continues 
to be an aggressive and life-threatening cancer. With approved drugs providing 
only modest survival benefits, there is an increasing interest on improving 
symptoms and health-related quality of life (HRQoL). The aim of this review is to 
understand the impact of mCRPC treatments on HRQoL. METHODS: The search 
was conducted on PubMed®. Additional articles were found from cross-
referencing, and on ASCO and ESMO websites. A multi-step approach ensured 
that a wide range of mCRPC studies were reviewed. The search was limited to 
